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Abstract
Phosphorylated alpha-synuclein (p-α-syn) containing Lewy bodies (LBs) and Lewy neurites (LNs) are
neuropathological hallmarks of Parkinson’s disease (PD) in the central nervous system (CNS). Since they have been
also demonstrated in the enteric nervous system (ENS) of PD patients, the aim of the study was to analyze enteric
p-α-syn positive aggregates and intestinal gene expression. Submucosal rectal biopsies were obtained from patients
with PD and controls and processed for dual-label-immunohistochemistry for p-α-syn and PGP 9.5. p-α-syn positive
aggregates in nerve fibers and neuronal somata were subjected to a morphometric analysis. mRNA expression of α-
syn and dopaminergic, serotonergic, VIP (vaso intestinal peptide) ergic, cholinergic, muscarinergic neurotransmitter
systems were investigated using qPCR. Frequency of p-α-syn positive nerve fibers was comparable between PD and
controls. Although neuronal p-α-syn positive aggregates were detectable in both groups, total number and area of
p-α-syn positive aggregates were increased in PD patients as was the number of small and large sized aggregates.
Increased expression of dopamine receptor D1, VIP and serotonin receptor 3A was observed in PD patients, while
serotonin receptor 4 and muscarinic receptor 3 (M3R) were downregulated. M3R expression correlated negative
with the number of small sized p-α-syn positive aggregates. The findings strengthen the hypothesis that the CNS
pathology of increased p-α-syn in PD also applies to the ENS, if elaborated morphometry is applied and give further
insights in altered intestinal gene expression in PD. Although the mere presence of p-α-syn positive aggregates in
the ENS should not be regarded as a criterion for PD diagnosis, elaborated morphometric analysis of p-α-syn
positive aggregates in gastrointestinal biopsies could serve as a suitable tool for in-vivo diagnosis of PD.
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Introduction
Parkinson’s disease (PD), a multicentric neurodegenera-
tive disorder that’s progression extends to decades [31],
is traditionally characterized by a loss of dopaminergic
neurons in the central nervous system (CNS), mainly
the brainstem, thus leading to characteristic cardinal
motor symptoms such as bradykinesia, tremor, rigidity,
and postural instability [43]. Degeneration of dopamin-
ergic neurons and the presence of misfolded alpha-
synuclein (α-syn) containing aggregates, namely Lewy
bodies (LBs) and Lewy neurites (LNs), are primary
pathological hallmarks of PD in the CNS. Within these
aggregates phosphorylation at serin129 is the most dom-
inant pathological α-syn form [3]. Recently, numerous
studies have indicated that besides the CNS also the
autonomic nervous system (ANS) is affected [36]. A
wide spectrum of non-motor manifestations involving
the urogenital and gastrointestinal (GI) system [32, 49]
has been observed leading to impaired urinary function
[5] and constipation [21] in patients with PD preceding
the motor symptoms.
One main division of the ANS is represented by the
enteric nervous system (ENS), a complex network
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integrated within the gut wall and organized in
mainly two ganglionated nerve plexus, the myenteric
and submucosal plexus [70]. Although the ENS works
autonomously from the CNS [18], many morpho-
logical and functional properties of the ENS resemble
the CNS rather than peripheral autonomic ganglia.
Thus, the ENS is considered as “the little brain within
the gut” [71], where it controls GI motility, mucosal
blood flow, ion and water transport and resorption
[24, 25]. Similar to the CNS, the functional integrity
of the ENS depends on intact synaptic transmission
and plasticity involving the synthesis, release and traf-
ficking of a broad range of inhibitory and excitatory
enteric neurotransmitters [23, 58].
Impairment of enteric neurotransmission is associated
with a wide spectrum of functional GI diseases charac-
terized by severe disturbances of GI motility [38] includ-
ing constipation [21]. Constipation is also one of the
leading premotor symptoms in patients with PD arguing
for lesions within the ENS accompanying the progres-
sion of the disease [49]. Moreover, the ENS has been in-
tensively discussed as a putative entry route of
neurotoxins in PD suggesting that neuropathological
processes spread via anatomically connected structures
from the ENS to the substantia nigra and then further
into other regions of the CNS [10, 47]. Thus, assessment
of ENS pathology associated with PD might offer a two-
fold option: (1) to use the ENS as “diagnostic window
into the CNS” [41] possibly allowing early in vivo diag-
nosis of PD and neuroprotective therapy, (2) to elucidate
the pathogenetic mechanisms underlying the high preva-
lence of GI symptoms, in particular chronic constipa-
tion, in patients with PD.
Biopsies of the GI tract are the most promising periph-
eral tissue source to investigate the intestinal pathology
linked to PD, as the tissue can be easily obtained by rou-
tine endoscopy and offers optimal conditions to study
the ENS in living patients [40]. However, the specifity
and usefulness of phosphorylated (p-α-syn) and native
α-syn detection in colonic biopsies as a reliable bio-
marker of PD remains unclear due to highly variable
results [2, 14, 17, 59] While some studies have regarded
α-syn/p-α-syn in LB or LN as a discriminator between
PD and controls [29, 39, 51, 52, 57], others have shown
that expression of enteric α-syn/p-α-syn can also be ob-
served in healthy subjects [2, 52, 61, 68]. In line with
these findings, we could show previously that α-syn ap-
pears to be abundantly expressed in the ENS of healthy
subjects and p-α-syn is not only detectable in patients
with PD but also in controls in an age-dependent
fashion [9].
Since p-α-syn is considered as the marker of choice to
delineate pathological aggregates from physiological α-
syn deposits, we aimed to further refine the assessment
of p-α-syn in the ENS by morphometric quantification
of phospho-serin129-α-synuclein (p-S129-α-syn) positive
aggregates both in neuronal somata and nerve fibers in
rectal biopsies of patients with PD and controls. More-
over, endoscopically retrieved biopsies allow to monitor
gene expression profiles associated with intestinal patho-
logical processes [16]. As PD is also associated with al-
tered neurotransmitter systems [35, 54], we further
analyzed the mRNA expression of α-syn and functionally




Patients (n = 12, age range: 43–77 y, mean age: 65 y)
were recruited from the Department of Neurology at the
University Hospital Schleswig-Holstein, Campus Kiel.
Diagnosis of PD was based on clinical examination by
neurologists according to UK Parkinson’s Disease Soci-
ety Brain Bank Clinical Criteria. Additional tests (e.g.
cranial MRI, DAT-Scan, levodopa test) were carried out
if required.
Controls
Control patients (n = 11, age range: 45–82 y, mean age:
66 y) were recruited from the Department of Internal
Medicine I at the University Hospital Schleswig-
Holstein, Campus Kiel, undergoing colonoscopy for
colorectal cancer screening or GI symptoms without
clinical evidence of neurological diseases. The study
protocol received approval from the Local Ethics Com-
mittee of the Faculty of Medicine, Christian Albrecht’s
University of Kiel, Germany (D455/10). From each pa-
tient a written informed consent was obtained.
Clinical studies
Unified Parkinson disease rating scale part III (UPDRS-III)
All patients were assessed by the UPDRS-III [26]. For
PD patients UPDRS-III was performed during ON-state.
In addition, control patients underwent a detailed neuro-
logical examination to rule out PD symptoms and other
neurodegenerative disorders.
Wexner constipation score
Symptoms of constipation were assessed by a validated
constipation scoring system according to Wexner [1].
The test allows evaluating the severity of constipation.
Retrieval and processing of rectal biopsies
All patients underwent routine colonoscopy following a
standard protocol. In each patient deep submucosal bi-
opsies (n = 2) were obtained from the upper dorsal rectal
wall and immediately fixed (4% paraformaldehyde in
PBS) and stored at 4 °C until processing for
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immunohistochemistry and subsequent morphometric
analysis. Additional biopsies (n = 4) for mRNA expres-
sions studies were able to be retrieved from 12 patients
with PD and 5 controls and immediately quick-frozen
with liquid nitrogen and stored at −70 °C. For immuno-
histochemical studies biopsies were embedded into par-
affin wax and cut orthogonally in serial sections (6 μm
thickness) including the mucosa and submucosa. Screen-
ing for submucosal ganglia within the sections was per-
formed by conventional immunohistochemistry using
the pan-neuronal marker PGP 9.5 applied to every 7th
section (Fig. 1a). One adjacent section containing sub-
mucosal ganglia and nerve fibers was then used for sub-
sequent morphometric analysis.
Immunohistochemistry for PGP 9.5
Immunohistochemistry for the pan-neuronal marker
PGP 9.5 was carried out as described previously [9].
Briefly, sections were incubated with 3% hydrogen per-
oxide, rinsed in TBS-buffer (TRIS-buffered saline;
10 mM TRIS, 50 mM NaCl, pH 7.4), incubated over-
night with the polyclonal rabbit-anti-PGP 9.5 (PGP 9.5,
1:15000, Accurate Chemical & Scientific Corporation,
Westbury, USA) diluted in antibody diluent (Invitrogen,
Karlsruhe, Germany) and incubated for 45 min with bio-
tinylated goat anti-rabbit IgG (1:400, DAKO, Hamburg,
Germany). After washing three times with TBS, sections
were incubated for 45 min with an avidin-biotin-
complex (Vectastain ABC Standard, Vector Laboratories,
Burlingame, USA) conjugated with horseradish peroxid-
ase. 3, 3′-diaminobenzidine (DAKO, Hamburg,
Germany) was used as substrate chromogen. Sections
were counterstained with Meyer’s hematoxylin. Stained
sections were analyzed by a light microscope (Nikon
6000, Nikon, Tokyo, Japan) coupled to a digital camera
(Digital Sight, Nikon, Tokyo, Japan). Data acquisition
was performed with NIS-Elements BR 3.2 software
(Nikon, Tokyo, Japan). Omission of the primary or sec-
ondary antibody served as negative controls.
Dual-label fluorescence immunohistochemistry for p-α-
syn and PGP 9.5
Sections were pre-treated with citrate buffer (pH 6.0,
95 °C water bath) for 25 min followed by overnight incu-
bation with a monoclonal mouse-anti-phospho-S129-α-
syn antibody (Wako Clone: pSyn64, 1:1.000, Wako
Chemicals GmbH, Neuss, Germany) in antibody diluent
(Invitrogen, Karlsruhe, Germany) as primary antibody.
The antibody was tested on human colonic and rectal
carcinoma specimens and brainstem material from pa-
tients with Dementia with Lewy bodies in previous ex-
periments [9]. After washing with TBS sections were
incubated with goat anti-rabbit AlexaFluor488 antibody
in antibody diluent (1:250, Invitrogen, Karlsruhe,
Germany) as secondary antibody for 2 h. Sections were
co-incubated with rabbit-anti-PGP 9.5 (PGP 9.5,
Fig. 1 Methodical procedure of morphometric analysis of p-α-syn positive aggregates in neuronal somata of submucosal ganglia. a Screening of
submucosal ganglia in orthogonal sections of a deep submucosal biopsy containing the mucosal and submucosal layer. Ganglia (arrowhead in (a)
and inlet of a) and nerve fibers of the submucosal plexus were identified by conventional immunohistochemistry with the pan-neuronal marker
PGP 9.5. b Dual-label immunohistochemistry with PGP 9.5 (red) and p-α-syn (green) of a submucosal ganglion. Number and area of neurons
detected by the pan-neuronal marker PGP 9.5 were recorded (c, blue circles). d Insert from c. Total number and area of p-α-syn positive structures
per neuron was calculated in photographs displayed in reverse grey-scale mode. p-α-syn positive aggregates were subdivided into three groups
according to size (L = large size, M =medium size, S = small size). Nuclear counterstain with DAPI (blue), bars (a): 500 μm, inlet in (a) = 100 μm: (b-d):
20 μm. e To determine the threshold between medium and large size p-α-syn positive aggregates the crossing point of frequency distribution curves
of p-α-syn positive aggregates in patients with PD (blue squares) and controls (red triangles) was defined (black arrow)
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1:15000, Accurate Chemical & Scientific Corporation,
Westbury, USA). Secondary antibody incubation was
carried out with goat-anti-mouse AlexaFluor546 anti-
body (1:250; Invitrogen, Karlsruhe, Germany) for 2 h. Fi-
nally, all sections were stained with DAPI (Roche,
Mannheim, Germany) to visualize cellular nuclei. Fluor-
escence signals were detected with a fluorescence micro-
scope (Axiovert 200 M), (Zeiss, Göttingen, Germany),
coupled to a digital monochrome camera (Axiocam) and
captured with Axiovision software (Zeiss, Göttingen,
Germany). Omission of the primary or secondary anti-
body served as negative controls.
Quantitative morphometric analysis
Presence of p-α-syn positive structures
Sections from patients with PD and controls were
assessed for the presence of p-α-syn positive structures.
Screening of p-α-syn immunoreactive signals within bi-
opsies was conducted separately for neuronal somata
and nerve fibers. The portion of patients with PD and
controls showing either p-α-syn positive neuronal
somata or nerve fibers was calculated and expressed as
percentage. In one control biopsy no ganglia could be
found. Thus, this biopsy was only used for calculating
the portion of p-α-syn positive nerve fibers.
Number and area of p-α-syn positive structures in neurons
All submucosal ganglia detected by the pan-neuronal
marker PGP 9.5 were included in the morphometry. The
ganglionic area as well as the area and number of neurons
per ganglion were calculated (Fig. 1b,c). Mean neuronal
area, mean ganglionic area and mean neuronal number
per ganglionic area were calculated for controls and pa-
tients with PD (Additional file 1: Figure S2a-c). For each
neuron, the total number and area of p-α-syn positive ag-
gregates were recorded using the software ImageJ [60].
The total number of p-α-syn aggregates/neuron (Fig. 4a),
the total area of p-α-syn positive aggregates/neuron
(Fig. 4b), the total area of p-α-syn aggregates/neuronal
area in % (Fig. 4c) and the total number of p-α-syn posi-
tive aggregates/neuronal area in μm (Fig. 4d) were calcu-
lated for controls and patients with PD.
Classification of small, medium and large size p-α-syn positive
neuronal aggregates
Given the fact, that p-α-syn positive aggregates largely
differed in size, they were further subdivided in small
size, medium size and large size p-α-syn aggregates. Cut-
off values were carried out as follows: Area of small size
p-α-syn aggregates ≤ 0.1 μm2 was set to 0.06 μm2 corre-
sponding to the mean of 10 calculated areas that exhib-
ited a size ≤ 0.1 μm2 (Fig. 1d). For discrimination
between medium and large size p-α-syn aggregates, fre-
quency distribution curves were performed for both
patients with PD and controls. The area was subdivided
in intervals of 0.5 μm2 (range: 0–100 μm2) and the fre-
quency of p-α-syn positive aggregates per interval was
determined (Fig. 1e). The crossing point (arrow in e,
1.5 μm2) of both frequency distribution curves was de-
fined as threshold between medium and large p-α-syn
positive aggregates (Fig. 1e). Medium sized p-α-syn posi-
tive aggregates were thus defined as structures with
size > 0.06 μm2 and ≤1.5 μm2, whereas large sized p-α-
syn positive aggregates included all structures with size >
1.5 μm2 (Fig. 1d).
Gene expression studies
RNA extraction and reverse transcription
Extraction of total RNA from quick-frozen biopsies were
performed using the NucleoSpin total RNA/Protein iso-
lation kit (Machery-Nagel, Düren, Germany) according
to the manufacturer’s instructions. Total RNA was
eluted in a volume of 60 μl H2O. Genomic DNA was
digested for 15 min with 1.5 U of DNAse I (Sigma-Al-
drich, Munich, Germany) at room temperature. Reverse
transcription was carried out in a total volume of 30 μl
containing 375 ng random hexamer primers (GE Health-
care, Freiburg, Germany), 0.5 mM dNTPs (Promega,
Mannheim, Germany), 0.01 M DTT, 1 x reaction buffer,
and 150 U Superscript II Reverse Transcriptase (Invitro-
gen, Karlsruhe, Germany). The annealing step was car-
ried out at 25 °C for 10 min, elongation at 25 °C for
10 min, and denaturation at 70 °C for 15 min.
Real-time quantitative PCR (qPCR)
Gene expression was determined by real time quantita-
tive polymerase chain reaction (qPCR) performed in 96
well plates in duplicate reactions, respectively. Each re-
action (20 μl) contained 1 × qPCR Master Mix Plus
(Eurogentec, Cologne, Germany), 900 nM primers, 225
nM hybridization probe and 2 μl of total cDNA. qPCR
product accumulation was monitored by the ABI Prism
7700 Sequence Detection System (TaqMan, Applied Bio-
systems, CA, U.S.A.) over 45 cycles. Each cycle consisted
of a denaturation phase (15 s at 95 °C) and a
hybridization/elongation phase (1 min at 60 °C). Genes
with primer and probes are listed in Table 1. The data
were normalized to expression levels of the housekeep-
ing gene hypoxanthine-guanine phosphoribosyltransfer-
ase (HPRT) expressed as fold increase and presented as
mean ± SEM.
Statistical analysis
Data were analyzed by Mann–Whitney U test (PrismTM,
GraphPad, Sand Diego, USA) and differences between
groups were considered significant if p < 0.05 (*), p < 0.01
(**), or p < 0.001 (***). For correlation analysis Spear-
man’s rank correlation calculated by statistical software
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R 2.8.0 [53] was used and p-values were adjusted for
multiple comparison using the method of Holm [30].
Clinical and morphometric data are documented as




The clinical semi-quantitative UPDRS-III (motor symp-
tom score, 0–108) yielded a mean score of 26.5 ± 16.1 in
patients with PD and 0 in controls (Additional file 2:
Figure S1a).
Wexner constipation score
The Wexner constipation score (constipation symp-
toms, 0–20) yielded a mean score of 4.1 ± 5 in pa-
tients with PD and 1.6 ± 4.2 in controls (Additional
file 2: Figure S1b). Although the mean value was
higher in patients with PD compared to controls, the
difference was not statistically significant.
Morphometric analysis of ganglia and neurons
In controls (n = 10) 51 ganglia with an overall number of
156 neurons could be detected, in patients with PD (n =
12) 48 ganglia with an overall number of 88 neurons
could be detected. Mean neuronal area was not signifi-
cant altered (248.2 ± 34.45 μm2) in PD patients com-
pared to controls (282.8 ± 49.65 μm2) (Additional file 1:
Figure S2a). Mean ganglionic area of PD patients (1264
± 188.4 μm2) was slightly but not significantly decreased
compared to controls (855.9 ± 143.7 μm2). (Additional
file 1: Figure S2b).
Mean neuronal number per ganglionic area of patients
with PD was not significant altered (0.002698 ±
0.0004841 number/μm2 ganglion for controls; 0.002814
± 0.0004843 number/μm2 ganglion for patients with PD)
(Additional file 1: Figure S2c).
Pattern and detection rate of p-α-syn immunoreactivity
Staining pattern of p-α-syn positive neuronal somata and
nerve fibers
p-α-syn immunoreactive signals were detected in nerve
fibers as discontinuous or punctate staining pattern in
both patients with PD and controls (Fig. 2a-f ). However,
not all of the PGP 9.5 positive nerve fibers were also im-
munoreactive for p-α-syn, and in some instances immu-
noreactivities for p-α-syn and PGP 9.5 did not
completely merge (Fig. 2c,f ). Within submucosal ganglia
p-α-syn immunoreactive signals were mainly detected in
neuronal somata of both patients with PD and controls
exhibiting aggregates of different sizes (Fig. 2g-l). No p-
α-syn positive staining was found in cell nuclei, however
slight punctate signals were discernible in the ganglionic
neuropil.
Detection rate of p-α-syn positive neuronal somata and
nerve fibers
In both patients with PD and controls p-α-syn immuno-
reactive signals were readily detectable within the sub-
mucosal plexus. While p-α-syn positive aggregates in
neuronal somata could be identified in each biopsy ob-
tained from healthy subjects as well as patients with PD
(Fig. 3a), p-α-syn positive nerve fibers were not consist-
ently detectable. In controls, 4 (36%) out of 11 individ-
uals showed positive p-α-syn signals in nerve fibers, in
the PD group, only 3 (25%) out of 12 patients displayed
p-α-syn positive nerve fibers (Fig. 3b).
Quantitative morphometric analysis of p-α-syn positive
aggregates
As p-α-syn immunoreactive signals were detected in
submucosal neurons in both controls and patients with
PD (Fig. 2), we performed quantitative morphometric
analysis to further test whether p-α-syn immunoreactive
aggregates differed between groups in regards to num-
ber, area and size.
Number and area of p-α-syn positive aggregates
The total number of p-α-syn positive aggregates per
neuron was signficantly higher in patients with PD (88 ±
42 p-α-syn positive aggregates/neuron) compared to
controls (28 ± 15 p-α-syn positive aggregates/neuron)
(Fig. 4a). Patients with PD also showed a significantly in-
creased total area occupied by p-α-syn positive aggre-
gates within neurons (17.40 ± 8.06 μm2 p-α-syn positive
aggregates/neuron) compared to controls (10.83 ±
Table 1 Primer for target-genes used in quantitative-real-time PCR (qPCR). DRD1 primer was bought from ThermoFisher Scientific
(Hs00265245_s1) as was DRD2 primer (MS00241436)
gene forward primer reverse primer probe
HPRT 5′-tgaacgtcttgctcgagatgtg-3′ 5′-ccagcaggtcagcaaagaattt-3′ 5′-tgggaggccatcacattgtagcc-3′
SNCA 5′-ccaaagagcaagtgacaaatgttg-3′ 5′-agccagtggctgctgcaat-3′ 5′-tgacgggtgtgacagcagtagccca-3′
5HT3AR 5-ggctggtgcacaagcaagac-3′ 5-ggctggtgcacaagcaagac-3′ 5-ctgcttggctgcgtcacctggttct-3′
5HT4R 5′-attccgggttgaacccttttc-3′ 5′-aggtcttcggtagcgctcatc-3′ 5′-acgtgccttcctcatcatcctct-3′
M3R 5′-cagctgcatacccaaaaccttt-3′ 5′-tgaatgttttgttgcacagagcata-3′ 5′-caacagcaccgtgaaccccgtgtg-3′
VIP 5′-aataaggcccagctccttgtg-3′ 5′-cccaacctgagagcagaaggt-3′ 5′-cttctcacagacttcggcatggc-3′
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5.77 μm2 p-α-syn positive aggregates/neuron) (Fig. 4b).
When normalized to the neuronal area, the total area of
p-α-syn positive aggregates was also significantly in-
creased in patients with PD (9.261 ± 1.733%) compared
to controls (4.958 ± 0.717%) (Fig. 4c). Also total number
of p-α-syn positive aggregates per neuronal area was sig-
nificantly increased in patients with PD (0.5553 ± 0.1450)
when compared to controls (0.2147 ± 0.03874) (Fig. 4d).
Distribution of p-α − syn positive aggregates according to
size
p-α − syn positive aggregates were subdivided according
to size into small, medium and large size p-α − syn ag-
gregates and quantified for both groups. Whereas for
medium size p-α − syn aggregates no significant differ-
ence was found between patients with PD (3.16 ± 1.70)
and controls (5.34 ± 3.11) (Fig. 5b), patients with PD
Fig. 3 Presence of p-α-syn positive neuronal somata and nerve fibers. While p-α-syn positive neuronal somata were found in all submucosal biopsies
of patients with PD and controls (a), p-α-syn positive nerve fibers were detected in 4 (36%) out of 11 control individuals and 3 (25%) out of 12 patients
with PD, respectively (b)
Fig. 2 Dual-label fluorescence immunohistochemistry of p-α-syn and PGP 9.5 in submucosal ganglia and nerve fibers. p-α-syn immunoreactive
signals (red) were detected in nerve fibers visualized by PGP 9.5 (green) as inhomogeneous and punctate staining pattern in both controls (a-c)
and patients with PD (d-f). However, not all of the PGP 9.5 positive nerve fibers were also immunoreactive for p-α-syn (arrowheads in c and f).
Within submucosal ganglia visualized by PGP 9.5 (red) p-α-syn immunoreactive signals (green) displayed aggregates of different sizes
mainly detected in neuronal somata of both controls (g-i) and patients with PD (j-l). No p-α-syn positive staining was found in cell nuclei,
but slight punctate signals were discernible in the ganglionic neuropil. Nuclear counterstain with DAPI (blue), bars: 20 μm
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showed increased number of both small size (80.52 ±
44.47) and large size (3.20 ± 1.76) p-α − syn aggregates
per neuron compared to controls (21.33 ± 14.40, 1.67 ±
1.51) (Fig. 5a,c). Moreover, calculation of the relative dis-
tribution of p-α − syn positive aggregates (Fig. 5d) re-
vealed a different distributional pattern between patients
with PD and controls. While patients with PD showed
90% ± 7% small size 6% ± 5.5% medium sized and 4% ±
4.9% large size p-α − syn aggregates, controls displayed
74% ± 13%, 19% ± 11% and 7% ± 6.7% p-α − syn aggre-
gates, respectively.
Clinicopathological correlation analysis in patients with PD
Correlation analysis of results obtained from the
UPDRS-III scale and Wexner Score showed no correl-
ation between the severity of PD symptoms and of con-
stipation symptoms (Spearman correlation coefficient
(rs) = −0.249, adjusted p value = 1). Also no correlation
between histological findings and UPDRS-III results was
found (total area of p-α − syn aggregates/neuron, rs =
0.252, p = 1; total number of p-α − syn aggregates/
neuron, rs = −0.148, p = 1; large size p-α − syn aggre-
gates/neuron, rs = 0.329, p = 1; medium size p-α − syn ag-
gregates/neuron, rs = −0.192, p = 1; small size p-α − syn
aggregates/neuron. rs = −0.148, p = 1). Finally, no correl-
ation was observed between histological findings and
Wexner Score results (total area of p-α − syn aggregates/
neuron, rs = 0.252, p = 1; total number of p-α − syn ag-
gregates/neuron, rs = −0.148, p = 1; large size p-α − syn
aggregates/neuron, rs = 0.329, p = 1; medium size p-α −
syn aggregates/neuron, rs = −0.192, p = 1; small size p-α
− syn aggregates/neuron. rs = −0.148, p = 1).
Gene expression analysis
mRNA expression was analyzed for α − syn (SNCA) and
selected genes of enteric neurotransmitter systems in-
cluding dopaminergic, serotonergic, and cholinergic re-
ceptors, as well as the neurotransmitter vasoactive
intestinal peptide (VIP). SNCA showed no difference in
mRNA expression between patients with PD and con-
trols (Fig. 6a). While mRNA expression of dopamine re-
ceptor D1 subtype (DRD1) exhibited a significant
increase in patients with PD (Fig. 6b), mRNA expression
of D2 subtype (DRD2) remained unaltered (Fig. 6c).
mRNA expression of the subunit A of the type 3 recep-
tor for 5-hydroxytryptamine (serotonin) (5HT3AR) was
significantly up-regulated in patients with PD (Fig. 6d),
whereas 5-hydroxytryptamine (serotonin) receptor 4
(5HT4R) was significantly down-regulated (Fig. 6e).
mRNA expression of the muscarinic acetylcholine recep-
tor M3 (M3R) was significantly decreased (Fig. 6f ),
mRNA expression of VIP was significant up-regulated in
patients with PD (Fig. 6g).
Fig. 4 Number and area of p-α-syn positive aggregates. The total number of p-α-syn positive aggregates per neuron (a) and the area of p- α -syn
positive aggregates per neuron (b) are significantly increased in patients with PD (n = 12) compared to controls (n = 10). The percentage of p-α-
syn positive aggregates per neuron was significant increased in patients with PD (c) as was the total number of p-α-syn positive aggregates normal-
ized to the neuronal area (d). Data are presented as mean ± SEM; *p < 0.05 vs control; ***, p < 0.001 vs control
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Correlation analysis between histological findings and
gene expression data
Analysis of correlation between p-α-syn positive aggre-
gates (total number, total area, number of small, medium
and large size p-α − syn aggregates) and gene expression
data showed no correlation except for one negative cor-
relation between the number of small size p-α-syn posi-
tive aggregates and gene expression levels of the
muscarinic acetylcholine receptor M3 (M3R), independ-
ent of the different groups (Spearman correlation coeffi-
cient (rs): −0.72, adjusted p-value < 0.0001) (Fig. 7).
Correlation between the number of small size p-α-syn
positive aggregates and gene expression levels of the
muscarinic acetylcholine receptor M3 (M3R) dependent
on the groups showed no significant correlation in the
PD group (rs = −0.356, p = 1) and control group (rs =
0.62, p = 1).
Discussion
Positive p-α-syn staining in patients with PD and controls
Several in vivo studies of patients with PD using α-syn
and/or p-α-syn immunohistochemistry applied to GI
tract biopsies reported different results in positive stain-
ing rates (for reviews see [2, 59, 64]) with a range from 5
to 100% for PD and from 0 to 100% for controls. The
high variability of these staining rates might be explained
by the different GI tract sites studied and technical
work-up of biopsies (e.g. tissue handling, fixation, anti-
gen retrieval, primary antibodies). In most of the studies
p-α-syn immunoreactivity was not observed in healthy
controls suggesting p-α-syn detection as an useful and
specific tool for identifying patients with PD [29, 52, 57].
However, a few studies [9, 52, 68] reported the pres-
ence of p-α-syn in colonic biopsies also in healthy con-
trols. By using conventional immunohistochemistry and
the highly specific PET-blot technique Visanji et al. re-
vealed p-α-syn positive aggregates in mucosal biopsies of
all healthy individuals investigated [68]. The authors
concluded that enteric p-α-syn immunoreactivity is not
an appropiate discriminator between healthy controls
and patients with PD. In line with these findings, we
could also observe positive p-α-syn staining not only in
patients with PD but also in all biopsies obtained from
controls. By using fluorescence p-α-syn immunohisto-
chemistry applied to rectal wholemount biopsies,
Pouclet et al. found mild somatic labelling of submuco-
sal neurons both in patients with PD and controls and
described dot-like pathological inclusions in p-α-syn
Fig. 5 Distribution of p-α-syn positive aggregates according to size. Whereas for medium sized p-α-syn positive aggregates no significant differences
were found between patients with PD (n = 12) and controls (n = 10) (b), patients with PD showed increased numbers of both small sized (a) and large
sized (c) p-α-syn positive aggregates compared to controls. d Total number of p-α-syn positive aggregates per neuron was higher in patients with PD
compared to controls due to the high amount of small sized p-α-syn positive aggregates. The relative portion of small (S) sized p-α-syn aggregates
was higher in patients with PD, while the relative portion of medium (M) and large (L) sized p-α-syn aggregates were higher in controls (d). Data are
presented as mean ± SEM; *p < 0.05 vs control; ***, p < 0.001
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positive structures of patients with PD compared to con-
trols. Most of these structures are immunoreactive for
the neuronal marker neurofilament 200 kDa, but some
of the inclusions do not display neurofilament 200 kDa
immunoreactivity, even though the authors find, that
their morphology is highly suggestive of Lewy neurites
[52]. Although our findings of p-α-syn positive neuronal
and non-neuronal submucosal structures (somatic label-
ing and dot-like pathological inclusions in p-α-syn posi-
tive nerve fibers, see Fig. 2) matched that of Pouclet and
colleagues, we did not find a significant difference in p-
α-syn staining rates in patients with PD, as p-a-syn
staining rates for nerve fibers in the present study were
25% for patients with PD and 36% for controls (Fig. 3b).
Since both studies used the same antibody, the discrep-
ancies might be related to technical aspects (e.g. unsec-
tioned wholemount tissue vs. tissue sections, different
antibody dilutions) or due to different biopsy sampling
sites in the GIT (colon vs. rectum).
In summary, given that p-α-syn was readily detect-
able within the submucosal plexus likewise in patients
with PD and controls, the present data suggest that
the mere presence of p-α-syn cannot be regarded as
specific for PD. For that reason we have carried out a
refined quantitative morphometric analysis of the
amount and pattern of p-α-syn aggregates aiming at
better discriminating between patients with PD and
healthy subjects.
Increased number and area of p-α-syn positive aggregates
in patients with PD
Morphological heterogeneity of LB-like structures has
been already observed in the CNS appearing as either
diffuse granular pleomorphic structures of variable shape
and size or intraneuritic dot-like structures [7, 20]. In
the ENS Gold et al. [27], have found also different stain-
ing pattern ranging from light, diffuse or punctate α-syn
positive labeling limited to nerve terminals to large clus-
tering of rings and puncta in some but not all myenteric
somata. Consistent with these findings we could also de-
scribe both homogeneous and granular p-α-syn labeling
in myenteric and submucosal ganglia [9].
Although additional parameters to characterize p-α-
syn aggregates in more detail (e.g. distributional pattern)
appear to be required, so far this quantitative morpho-
metric approach has not been carried out previously. In
fact, the assessment of the total number and area of p-α-
syn positive structures per neuron revealed that patients
with PD showed a significant increase of both parame-
ters compared to controls. The overlap of values be-
tween both groups was lower for the number of p-α-syn
positive structures per neuron suggesting that this
Fig. 6 Gene expression analysis of synuclein and enteric neurotransmitter systems. mRNA expression in submucosal biopsies of patients with PD
(n = 8-12) and controls (n = 2-5) showed no alteration in synuclein (SNCA, a) and D2 subtype of dopamine receptor (DRD2, c), whereas significant
upregulation of D1 subtype of dopamine receptor (DRD1, b), subunit A of type 3 receptor for 5-hydroxytryptamine (serotonin) (5HT3AR,
d), vasoactive intestinal peptide (VIP, g) was found in patients with PD. mRNA expression of 5-hydroxytryptamine (serotonin) receptor 4
(5HT4R, e) and muscarinic acetylcholine receptor M3 (M3R, f) were significantly down-regulated in patients with PD. Data were normalized
to the mRNA expression of the house-keeping gene HPRT and presented as mean ± SEM and expressed as fold induction.*, p < 0.05 vs
control; **, p < 0.01 vs control; ***, p < 0.001 vs control
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parameter discriminates even better between patients
with PD and controls than the area of p-α-syn positive
structures.
Distinct distributional pattern of p-α-syn aggregates
according to size in patients with PD
Further subdivision of neuronal p-α-syn aggregates ac-
cording to size revealed a significant increase of small
and large sized p-α-syn aggregates in patients with PD
compared to controls, while medium sized p-α-syn ag-
gregates were equally distributed in both groups. The
best discriminator was the number of small sized p-α-
syn aggregates - only one third of patients with PD fell
within the range of controls, whereas two thirds showed
values well above the control group.
The (patho-) physiological mechanisms leading to
the formation of differently sized p-α-syn aggregates
observed within the ENS remains unclear. The well-
known morphological heterogeneity of LBs within the
CNS has fed speculations that the spectrum of α-syn
inclusions could represent different stages of LB de-
velopment [28, 55]. Gomez-Tortosa et al. hypothesized
that clouds of rich α-syn containing structures could
represent very early stages of LB pathology. Such le-
sions would progress to more compact and better-
defined α-syn aggregates and some of these inclusions
could be recognized as pale bodies in H&E stain con-
sidered as precursors of LBs [69], which in turn con-
dense to classical LBs. As p-α-syn is a subcomponent
of LBs [62], it might be assumed that the differently
sized p-α-syn positive aggregates observed within en-
teric ganglia could represent different LB development
stages ranging from small sized granula to the assem-
bly and fusion into larger aggregates.
It is of note that although the number of small and
large sized p-α-syn aggregates was significant increased
in patients with PD, all three sizes of p-α-syn aggregates
were also observed in controls. This suggests that p-α-
syn aggregation in the gut is a physiological process, but
may be dysregulated and increased in patients with PD.
The following observations strengthen this hypothesis:
(1) Both p-α-syn and α-syn are physiologically expressed
in the human [8, 9] and rat ENS [50]. (2) α-syn aggre-
gates are primarily cytoplasmic [63] and although most
of the studies observed physiological cytoplasmic α-syn
as monomer [12], some studies indicate that α-syn can
assemble also physiologically as oligomers [6, 37] and
upon membrane binding as multimers [11]. (3) Environ-
mental toxins (e.g. rotenone) trigger PD-like progression
by promoting α-syn release from enteric neurons, uptake
by presynaptic neurites and retrograde transport to and
accumulation in neuronal somata. [48]. Thus, it is sug-
gestive that increased p-α-syn positive aggregates in en-
teric neurons, in particular the small sized type, in PD
patients reflect the inital steps of an enhanced α-syn re-
lease upon external insults.
Gene expression of α-syn
Interestingly, no difference in the SNCA mRNA expres-
sion between PD and controls was observed, even
though total number and area of p-α-syn positive aggre-
gates were significantly increased in PD patients. How-
ever, also in the CNS PD, particularly the sporadic form,
is not consistently associated with increased mRNA
levels of SNCA [15, 67]. In addition, some studies
showed that LB formation is also not associated with an
increase in SNCA mRNA expression [34]. In contrast to
that, α-syn secretion normally is associated with an in-
crease in SNCA mRNA expression [44]. This strengthen
the idea that our observed increase in neuronal p-α-syn
positive aggregates is the product of rather a disturbed
α-syn aggregation process than an increase in α-syn
secretion.
Altered gene expression of neurotransmitter systems
In line with our findings a decrease of 5-HT4 recep-
tors in the tunica muscularis has also been observed
in a mouse-model of PD [74]. Therefore, the dysregu-
lated 5-HT4 and 5-HT3 receptor mRNA expression
Fig. 7 Correlation analysis of p-α-syn positive aggregates and gene
expression profiles. Correlation analysis of p-α-syn positive aggregates
(total number, total area, number of small, medium and large
sized aggregates) and gene expression data identified a negative
correlation between small sized p-α-syn positive aggregates and
gene expression levels of the muscarinic acetylcholine receptor
M3 (M3R), with a Spearman correlation coefficient of −0.72 and
adjusted p-value of < 0.0001. Black filled circles showed data
points of the PD group; white circles showed data points of the
control group
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observed in our study might reflect mechanisms
underlying colonic dysmotility in PD. DA is known to
inhibit GI motility via D1 receptors [72] and the M3
receptor is an important subtype mediating the con-
traction of intestinal smooth muscle [66]. Thus, both
the significant upregulation of D1 receptor mRNA
and downregulation of M3 receptor mRNA may fur-
ther contribute to constipation symptoms in patients
with PD. However, the upregulation of VIP mRNA
does not fit into this concept, as this neuropeptide is
downregulated in patients with idiopathic constipation
[46]. Generally, interpretation of enteric neurotrans-
mitter disturbances observed within the mucosal/sub-
mucosal layer retrieved by biopsies should be made
carefully in regard to its effects on GI motility, as GI
motility is primary driven by the myenteric plexus.
Full-thickness biopsies including all enteric nerve
plexus would provide optimized conditions to study
these aspects. In addition in a previous study Annerino et
al. investigated the relative abundance of NO, VIP or TH
neurons between patients with PD and controls, by count-
ing nitric oxide synthase (NOS), VIP, or TH fluorescence
labelled neurons [4]. The authors reported no difference
in relative abundance of NO, VIP, or TH neurons in my-
enteric plexus of any GI segment of patients with PD.
Thus, neuropathology in myenteric neurons as causative
factor for PD-related GI dysmotility is still under
discussion.
Consistent with our results, reduced mucosal ex-
pression of 5-HT4 receptor and increased mucosal
expression of 5-HT3A receptors was also observed in
a mouse model of experimental colitis [45]. Addition-
ally, 5-HT4 receptor activation is linked to anti-
inflammatory effects in the GI system [76], and
increased mRNA expression of VIP was reported in
moderately inflamed mucosal epithelium [33]. These
data suggest a link between PD and inflammatory
processes at the level of the GI tract, as proposed by
Devos et al., who found striking similarity between
pro-inflammatory cytokine expression patterns in
bowel biopsies of PD patients and patients with in-
flammatory bowel diseases [19].
It has been postulated that the GI tract might be an
entry route for a still unknown agens or neurotoxin that
crosses the intestinal epithelial barrier, induces α-syn ag-
gregation in the ENS and migrates retrogradely via pro-
jecting neurons towards the CNS [10]. A disturbed
intestinal barrier function was recently observed in pa-
tients with PD [56]. In this context it is of note that in-
creased mRNA levels of DRD1 and DRD2 in the
intestinal mucosa after traumatic brain injury correlated
with an impaired intestinal mucosal barrier function
[73]. Thus, our observed upregulation of D1 receptor
could point to a disturbed intestinal epithelial barrier in
patients with PD. This hypothesis is in line with the im-
pressive down-regulation of the muscarinergic M3 re-
ceptor, as M3 receptor is involved in the regulation of
permeability in human jejunal epithelium and discussed
as main mediator of transcellular transport of macro-
molecules [13]. Of note, M3R is known as an activator
of cytoplasmatic phospholipase A2 via the activation of
protein kinase c (PKC) [75] and since PKC itself has
been shown to play a role in the modulation of tight
junction proteins such as occludin [65], it is possible,
that M3 receptors may be involved in the modulation of
epithelial barrier permeability both via modulation of
tight junction proteins and transcellular permeability in
patients with PD.
Correlation between p-α-syn positive aggregates and
gene expression data
Correlation analysis between p-α-syn positive aggregates
and gene expression data yielded a negative correlation
between the expression level of the M3 receptor and the
number of small sized p-α-syn positive aggregates, inde-
pendent of both groups where correlation was lost when
analysis was made separately. This suggested a direct
link between p-α-syn assembling in submucosal neurons
and transcript changing of M3R.
Positive correlation between mucosal α-syn staining
and increased intestinal permeability or bacterial trans-
location in patients with PD was found before by Forsyth
et al. [22]. Based on the widely accepted assumption that
α-syn aggregates are a consequence of oxidative injury
to neurons [62], the authors proposed that local oxida-
tive stress caused by the translocation of luminal bac-
teria products leads to α-syn missfolding, aggregation
and subsequent neuronal damage in the ENS. Since
M3R expression may play a role in modulating the epi-
thelial barrier, our observed direct negative correlation
between M3R expression and small sized p-α-syn aggre-
gates may further reflect a causality of increased intes-
tinal permeability and α-syn assembling in patients with
PD.
Interestingly, M3R activation is linked to α-syn in a
human dopaminergic cell line in which muscarinic re-
ceptor stimulation leads to translocation of oligomeric
α-syn from the plasma membrane to a light vesicle frac-
tion in the cytoplasm [42]. The authors suggest, that α-
syn could have a physiological role in the cell, in which
its release transiently disinhibits membrane bound
phospholipase LD2, freeing this lipase to function in
ligand-stimulated manner to muscarinic receptor endo-
cytosis. Our data therefore also suggest a physiological
process of α-syn aggregation, which is linked to M3R re-
ceptor expression and therefore perhaps dysregulated in
PD.
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Conclusions
In summary, we provide evidence that although sug-
gested in previous studies, the mere presence of p-α-syn
positive aggregates in the ENS cannot be regarded as a
diagnostic criterion for PD, as p-α-syn is also consist-
ently expressed in healthy controls. However, if a refined
morphometric analysis is applied, a specific pattern of p-
α-syn aggregates can be identified in patients with PD
distinct from controls. Moreover, altered gene expression
profiles observed in biopsies from patients with PD sug-
gest that PD is associated with inflammatory processes
and intestinal barrier dysfunctions possibly enhancing p-
α-syn assembling. Further studies are needed to proof
whether subtle quantitative and morphometric
characterization of enteric p-α-syn may be an additional
approach to allow diagnosis of PD by using GI biopsies.
Additional files
Additional file 1: Figure S2. Mean ganglionic area, mean neuronal
area and % p-a-syn positive aggregates per neuron of patients with PD
and controls. Mean neuronal area (a), mean ganglionic area (b) and mean
neuronal number per ganglionic area (c) exhibited no significant differ-
ence between patients with PD and controls. (TIF 2469 kb)
Additional file 2 Figure S1. UPDRS-III and Wexner constipation score.
(a) The clinical semi-quantitative UPDRS-III test (motor symptom score:
0–108) yielded a mean score of 26.5 ± 16.19 in patients with PD and
0 in controls. (b) The Wexner constipation score (constipation symptoms:
0–20) yielded a mean score of 4.1 ± 5 in patients with PD and 1.6 ± 4.2 in
controls. n = 10 controls, n = 12 patients with PD, *** p < 0.001 vs. controls.
(TIF 996 kb)
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